⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21553907 | 0.76 | — | — | |
| SCHEMBL3071837 | 0.76 | — | — | |
| SCHEMBL3071836 | 0.76 | — | — | |
| SCHEMBL15926696 | 0.67 | — | — | |
| SCHEMBL15945350 | 0.65 | — | — | |
| SCHEMBL15996708 | 0.65 | — | — | |
| SCHEMBL15291382 | 0.64 | — | — | |
| SCHEMBL18708517 | 0.64 | — | — | |
| SCHEMBL15786196 | 0.64 | — | — | |
| SCHEMBL20201199 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3248982-A1 | THIOSULFONATE REAGENTS FOR THE SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS | Wave Life Sciences Ltd. (SG) | 2017-11-29 | — | — | EP | disclosed |
| US-9783501-B2 | Substituted quinolines as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| US-9139529-B2 | Substituted quinoxalines as sodium channel modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140228371-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-14 | — | — | US | disclosed |
| EP-2732816-A1 | Use of amidoxime carboxylic acid esters and n-hydroxyguanidine carboxylic acid esters for producing prodrugs | Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG (DE) | 2014-05-21 | — | — | EP | disclosed |
| EP-2626350-A1 | CYCLOPROPANE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2013-08-14 | — | — | EP | disclosed |
| WO-2007106317-A2 | PHARMACEUTICAL COMBINATIONS OF HCV-PROTEASE AND -IRES INHIBITORS | SCHERING CORPORATION (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2006130552-A2 | METHODS OF TREATING HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130687-A2 | LIVER/PLASMA CONCENTRATION RATIO FOR DOSING HEPATITIS C VIRUS PROTEASE INHIBITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130688-A2 | COMPOUNDS FOR INHIBITING CATHEPSIN ACTIVITY | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130626-A2 | METHOD FOR MODULATING ACTIVITY OF HCV PROTEASE THROUGH USE OF A NOVEL HCV PROTEASE INHIBITOR TO REDUCE DURATION OF TREATMENT PERIOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130627-A2 | METHODS FOR TREATING HEPATITIS C | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2005058821-A1 | INHIBITORS OF HEPATITIS C VIRUS NS3/NS4A SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-06-30 | — | — | WO | disclosed |